MS and Demyelinating Disorders

Newly approved treatments in neuromyelitis optica spectrum disorder have shown efficacy in recent years, yet unaddressed concerns voiced by clinicians and patients living with the disease remain.

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]

The approval is supported by phase 3 data which showed ravulizumab-cwvz met its primary end point of time to first on-trial relapse, with no relapses observed in 58 patients with NMOSD over a median treatment duration of 73 weeks.

The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]

In a paradigm with many options, once multiple sclerosis is confirmed as a patient’s diagnosis, physicians are left with 1 question: What do we choose for long-term treatment?

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders and multiple system atrophy.

Transgender and gender-diverse patients have unique neurological considerations, but often, neurologists are unaware of the needs that are specific to this community.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 22, 2024.

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 32 minutes]

The professor of neurology at Johns Hopkins Medicine talked about modeling visual systems as an area of focus in clinical trials for multiple sclerosis as it may offer insights into neurodegeneration and neuroprotection. [WATCH TIME: 6 minutes]

The associate vice president of clinical Innovation and strategy and the health equity director at National MS Society talked about leveraging data mapping to bridge healthcare gaps and promote health equity in multiple sclerosis. [WATCH TIME: 4 minutes]

The professor of epidemiology at Karolinska Institutet talked about findings from a comprehensive study on the correlation between obesity and accelerated progression of multiple sclerosis. [WATCH TIME: 8 minutes]

A panel of experts MS specialists provided commentary on the clinical development of these therapies, some of the specific agents within the pipeline, and how to navigate potential safety concerns.

Join us on April 8 on our LinkedIn and X pages for our #PreAANChat premeeting social chat ahead of the 2024 American Academy of Neurology Annual Meeting!

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania discussed preclinical research on neural repair in multiple sclerosis at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]

Following the 2024 ACTRIMS Forum, the associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the need to build creative trials for multiple sclerosis treatments. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Purple Day and epilepsy awareness.

A recent analysis of a phase 2 trial showed that repeated intrathecal injections of MSC therapy led to significant reductions in serum biomarkers and improvements in neurological function for progressive MS.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 15, 2024.

A new feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

The delivery device is prefilled with the prescribed dose of Acthar Gel in 40- or 80-unit versions, and may help administration of the appropriate subcutaneous dose of Acthar Gel.